Congratulations Dr. Michael Kolinsky! CIHR funding announced for CCTG PR25

The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.

Of those Canadians diagnosed with prostate cancer each year, 25% have alterations in their genes that normally repair damage. These genes are called DNA damage response (DDR) genes which make cancer cells sensitive to a form of chemotherapy called platinum-based chemotherapy (PBC).

"This funding support from CIHR will allow us to conduct this innovative trial, which aims to improve outcomes for patients with advanced prostate cancer by leveraging existing biomarker testing and treatments," says Dr Michael Kolinsky, Medical Oncologist at the Cross Cancer Institute and CCTG PR25 study chair.

CIHR funding announced for CCTG PR25 | Canadian Cancer Trials Group (queensu.ca)